Sensei Biotherapeutics, Inc. (SNSE)

Oxford Ledge is still expanding full research coverage of SNSE. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.

Business summary

Sensei Biotherapeutics develops PIKTOR, a multi-targeted cancer therapy in clinical trials for endometrial and breast cancer.

Source: 10-K

Insider activity

5 recent insider (SEC Form 4) filings on record for SNSE. View the transactions in the terminal.

Source: SEC EDGAR (Form 4).

The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.